Truist Securities Maintains Hold on OrthoPediatrics, Raises Price Target to $38
Truist Securities Raises Price Target on OrthoPediatrics to $38 From $35, Maintains Hold Rating
OrthoPediatrics Analyst Ratings
OrthoPediatrics: Strong Q1 Performance Prompts Buy Rating and Raised Price Target
Buy Rating Affirmed for OrthoPediatrics Amid Strong Growth and Strategic Acquisitions
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)
Strong Buy Rating for OrthoPediatrics: Sustained Growth and Market Expansion Fuel Optimism
OrthoPediatrics Analyst Ratings
OrthoPediatrics (KIDS) Receives a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)
Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Compugen (CGEN) and OrthoPediatrics (KIDS)
OrthoPediatrics Earns Buy Rating From Analyst on Strong Q4 Performance and Promising Growth Outlook
OrthoPediatrics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)
Buy Rating for OrthoPediatrics: A Comprehensive Analysis of Market Position and Financial Growth Potential
OrthoPediatrics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Danaher (DHR), Blueprint Medicines (BPMC) and OrthoPediatrics (KIDS)
OrthoPediatrics (KIDS) Receives a Buy From BTIG
Truist Securities Maintains Buy on OrthoPediatrics, Raises Price Target to $39